Prospective Clinical Study to Observe the Efficacy and Safety of Tacrolimus in Refractory Rheumatoid Arthritis Patients for 6 Months Treatment in China

Status: Completed

Phase of Trial: Phase IV

Latest Information Update: 22 Nov 2023

Price : $35 ^*

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

16 Nov 2023 Status changed from active, no longer recruiting to completed.
04 Jun 2022 Primary endpoint has been met (Change from baseline Disease Activity Score 28 (DAS28-ESR) at 24 weeks) , according to Results presented at the 23rd Annual Congress of the European League Against Rheumatism
04 Jun 2022 Status changed to active, no longer recruiting , according to Results presented at the 23rd Annual Congress of the European League Against Rheumatism

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com